Canwis Porjects

With rich experience in Cannabis regulation, Canwis had assisted 3 public listed companies whereas 8 companies obtained the LPs, however, due to their confidential policies and NDA signed, part of our clients can be listed at the time being.

SynerGenetic Bioscience Inc

SynerGenetic Bioscience Inc. is a Canadian plant genetics research and development company focused on hemp strains. The Company is led by a management team with combined 35+ years cannabis and hemp industry experience and a clear vision of capitalizing on the growing cannabis, hemp, and cannabidiol (“CBD”) markets.
SG’s R&D team leveraged state of the art technology to identify optimal plant traits and developed SG’s first product – a hemp strain capable of producing 15%+ CBD content. The strain will be marketed to commercial hemp farmers facing agricultural challenges, high production costs, and difficulty in producing sufficient hemp biomass to cater to growing consumer demand and interest in CBD products. With high-yield CBD hemp biomass, commercial hemp farmers using SG strains can generate up to 7.5 times more revenue while minimizing production costs. SG’s first batch of seeds is currently undergoing final preparations at a British Columbia greenhouse facility and will be ready for sale by June of 2020. SG is now seeking financing to build up seed inventory in preparation for its initial sales.
Learn More

Late Stage LP

Acquiring a late-stage LP is a shortcut to enter the industry in one step.

A company located in BC, Canada, has obtained a “Confirmation of Readiness for a License” and “hemp cultivation license”, aimed to become a supplier of high-quality cannabis and CBD products.

The project has a 13-acre ground planting site, whereas plans to build a 18,000-foot indoor greenhouse facility, processing and extraction plants, facility is been designed with anti-oxidation material magnesium oxide wallboard as the main building material, and also uses outstanding fire prevention, anti-theft, ventilation, irrigation and lighting systems.
The project is expected to complete the site construction and license application in 2021. This acquisition is in the best timing to get into the Canadian LP ranks with low cost and risk.

XYNARx

Bringing Pharmaceutical solutions to hemp and cannabis industry, enhancing existing pharmaceutical products with plant-derived camabinoid through research and development.
R&D will be conducted in-house for incorporating Cannabinoids into number of Products. The company has focused on the following 5 major categories: supplement, nutraceuticals, inflammation and pain products (OTC), cannabinoid oils and generic products.
Targeting a $300 billion + and growing market, the company is applying for approval for NPN (Natural Product Number) and DIN (Drug Identification Number).
Learn More

Extrarize Global Inc

Technical EU GMP grade extraction base.

Extrarize Global includes a team with extensive industry experience in product R&D and marketing, gradually using a full range of technologies to ensure quality standards, vertically integrating business models to lock supply and demand sides, and EU GMP grades driving comprehensive domestic and international expansion.

The capacity is up to 400 pounds of biomass per hour, and automatic operation to minimizes labor costs. High-quality production results, the residual cannabinoid content is less than 1%; up to 85% of the extract can be recycled and reused by them technology, referring to other companies to reduce the amount of extract by 50%.

Cannabis REIT

A Real Estate Investment trust raises funds from outside sources and then uses this capital to purchase cannabis facilities or property from a cannabis company. It then leases the same property back to that firm. The business model can vary, of course, but effectively, the result is the same.
There are several benefits of this model for cultivators and investors.
Looking at cultivators first, partnering with a cannabis REIT (or selling your assets to lease them again) frees up much-needed cash that otherwise would be tied up in real estate. This allows growers to focus more cash into areas that need it the most, especially in the early stages of business—such as brand and product development. After all, cannabis REITs are buying company assets worth millions of dollars. Receiving that sizeable influx of cash can help growers flourish. As stated, this business model will also benefit many investors and here’s why: Because a cannabis REIT doesn’t actually grow marijuana, it avoids much of the legal and regulatory issues that are still materializing in the space. Moreover, it is providing an important resource to the industry—cash to help fund growth. Therefore in backing these shares, investors know they are taking a piece of the cannabis pie, but have less to worry about in terms of individual operational performances, or laws and regulations that may greatly impact key revenue drivers of a standard cannabis cultivator.
Another favorable mention is that a REIT is required by law to distribute at least 90% of its taxable income to its shareholders as dividends. Further, those dividends are deductible from the REIT’s taxable income. Therefore investors can be certain to be paid out more often from this type of cannabis investment.

Contact us!

Give us a call or drop by anytime, we endeavour to answer all enquiries within 24 hours on business days.